Article ID Journal Published Year Pages File Type
8668397 Journal of Clinical Lipidology 2018 18 Pages PDF
Abstract
PCSK9 antibodies have significant effects on reducing LDL-C levels and improve cardiovascular outcomes. These antibodies have a satisfactory safety profile, which suggests that they are suitable for use as a long-term treatment.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine
Preview
Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials
Authors
, , , ,